Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie Goletz

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
JAMA Dermatology|March 30, 2022
Clinical and Serological Characterization of Orf-Induced Immunobullous DiseaseKaan Yilmaz, Stephanie Goletz, Henri H Pas, et al.
Journal of Autoimmunity|September 17, 2018
IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoidLenche Chakievska, Maike M Holtsche, Axel Künstner, et al.
The Journal of Investigative Dermatology|September 25, 2024
Anti-Laminin β4 IgG Drives Tissue Damage in Anti-p200 Pemphigoid and Shows Interactions with Laminin α3 and γ1/2 ChainsManuela Pigors, Stephanie Goletz, Yao Wang, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 6, 2025
Clinical and immunopathological spectrum of immunoglobulin M pemphigoid: a multicenter case seriesKaan Yilmaz, Stephanie Goletz, Christoph M Hammers, et al.
Journal of the American Academy of Dermatology|November 22, 2023
Laminin β4 is a constituent of the cutaneous basement membrane zone and additional autoantigen of anti-p200 pemphigoidStephanie Goletz, Manuela Pigors, Tina Rastegar Lari, et al.
The Journal of Pathology|November 6, 2023
Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockadeManuela Pigors, Sabrina Patzelt, Niklas Reichhelm, et al.
Journal of the American Academy of Dermatology|January 1, 2017
Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseasesNina van Beek, Cornelia Dähnrich, Nora Johannsen, et al.
Frontiers in Immunology|October 17, 2022
Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseasesSaeedeh Ghorbanalipoor, Shirin Emtenani, Melissa Parker, et al.
Frontiers in Immunology|December 19, 2022
Corrigendum: Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseasesSaeedeh Ghorbanalipoor, Shirin Emtenani, Melissa Parker, et al.
Biomolecules|March 28, 2026
Complement Activation May Drive the Pathogenicity of Anti-α6 and Anti-β4 Integrin Antibodies In VivoGefei Du, Shirin Emtenani, Dennis Niese, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
JAMA Dermatology|March 30, 2022
Clinical and Serological Characterization of Orf-Induced Immunobullous DiseaseKaan Yilmaz, Stephanie Goletz, Henri H Pas, et al.
Journal of Autoimmunity|September 17, 2018
IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoidLenche Chakievska, Maike M Holtsche, Axel Künstner, et al.
The Journal of Investigative Dermatology|September 25, 2024
Anti-Laminin β4 IgG Drives Tissue Damage in Anti-p200 Pemphigoid and Shows Interactions with Laminin α3 and γ1/2 ChainsManuela Pigors, Stephanie Goletz, Yao Wang, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 6, 2025
Clinical and immunopathological spectrum of immunoglobulin M pemphigoid: a multicenter case seriesKaan Yilmaz, Stephanie Goletz, Christoph M Hammers, et al.
Journal of the American Academy of Dermatology|November 22, 2023
Laminin β4 is a constituent of the cutaneous basement membrane zone and additional autoantigen of anti-p200 pemphigoidStephanie Goletz, Manuela Pigors, Tina Rastegar Lari, et al.
The Journal of Pathology|November 6, 2023
Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockadeManuela Pigors, Sabrina Patzelt, Niklas Reichhelm, et al.
Journal of the American Academy of Dermatology|January 1, 2017
Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseasesNina van Beek, Cornelia Dähnrich, Nora Johannsen, et al.
Frontiers in Immunology|October 17, 2022
Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseasesSaeedeh Ghorbanalipoor, Shirin Emtenani, Melissa Parker, et al.
Frontiers in Immunology|December 19, 2022
Corrigendum: Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseasesSaeedeh Ghorbanalipoor, Shirin Emtenani, Melissa Parker, et al.
Biomolecules|March 28, 2026
Complement Activation May Drive the Pathogenicity of Anti-α6 and Anti-β4 Integrin Antibodies In VivoGefei Du, Shirin Emtenani, Dennis Niese, et al.
Pageof 4